Efficacy of stereotactic radiotherapy for brain metastases using dynamic jaws technology in the helical tomotherapy system

Murai, Taro; Hayashi, Akira; Manabe, Yoshihiko; Sugie, Chikao; Takaoka, Taiki; Yanagi, Takeshi; Oguri, Tetsuya; Mori, Yoshimasa; Shibamoto, Yuta

doi:10.1259/bjr.20160374

Cited by 6 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But no significant differences in dose distribution, clinical efficacy and toxicity were observed in study [5]. Thus, this technology is most useful in SRT.…”

Section: Discussionmentioning

confidence: 82%

See 1 more Smart Citation

Specific Approaches to Planning of Patients With Primary and Secondary Brain Tumors Using the Tomotherapy Planning System

Odarchenko¹,

Gumeniuk²,

Gumeniuk³

et al. 2017

RAD Conference Proceedings

View full text Add to dashboard Cite

Abstract. Nowadays only several medical centers of Ukraine are equipped with special linear accelerators for treating patients using Image-Guided Radiation Therapy (IGRT) and Intensity-Modulated Radiotherapy (IMRT), apart from 3DCRT methods. Sequential (SEQ) and Simultaneous Integrated Boost (SIB) are common IMRT techniques for whole brain irradiation and metastasis treatment using TomoTherapy system TomoHD. The radiotherapy system, mentioned above, is innovation for oncological diseases treatment in Ukraine as well as in post Soviet Union countries in general. Thus, one of main goals of the work is to define the quality of different therapeutic plans, to identify and describe the main features of treatment plans preparation and creating and to describe some specific approaches for SIB and SEQ techniques in planning of patients with brain tumors using the TomoTherapy Planning System.

show abstract

“…But no significant differences in dose distribution, clinical efficacy and toxicity were observed in study [5]. Thus, this technology is most useful in SRT.…”

Section: Discussionmentioning

confidence: 82%

“…At least, 95% of the PTV volume must be covered by 95% of the prescribed dose, if OAR is partially or fully included in PTV, and there is no possibility to irradiate it with the full prescribed dose [5]. Each individual case is always discussed with a therapist.…”

Section: Preliminary Assessment Planmentioning

confidence: 99%

Specific Approaches to Planning of Patients With Primary and Secondary Brain Tumors Using the Tomotherapy Planning System

Odarchenko¹,

Gumeniuk²,

Gumeniuk³

et al. 2017

RAD Conference Proceedings

View full text Add to dashboard Cite

show abstract

“…Even if the phase II trial is positive (i.e., p < 0.20), that is not considered conclusive without a subsequent phase III trial. The results of the previous study of irradiation at intervals demonstrated a 1-year IC-LC of 93% [ 13 ]. Assuming a 1-year IC-LC of 70% for Arm 1 (consecutive daily irradiation) and 90% for Arm 2 (irradiation at two- to three-day intervals) and a 1-year OS of 50% for target patients, with 80% power, alpha of 0.20, an 5% lost follow-up rate, accrual time of 4 years and a total trial time of 5 years, 70 patients will be required (35 in Arm 1 and 35 in Arm 2).…”

Section: Discussionmentioning

confidence: 99%

Daily irradiation versus irradiation at two- to three-day intervals in stereotactic radiotherapy for patients with 1-5 brain metastases: study protocol for a multicenter open-label randomized phase II trial

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background Radiobiological daily changes within tumors are considered to be quite different between stereotactic radiotherapy (SRT) (e.g., 50 Gy in 4 fractions) and conventional radiotherapy (e.g., 60 Gy in 30 fractions). We aim to assess the optimal interval of irradiation in SRT and compare outcomes of daily irradiation with irradiation at two- to three-day intervals in SRT for patients with one to five brain metastases (BM). Methods This study is conducted as a multicenter open-label randomized phase II trial. Patients aged 20 or older with one to five BM, less than 3.0 cm diameter, and Karnofsky Performance Status ≥70 are eligible. A total of 70 eligible patients will be enrolled. After stratifying by the number of BMs (1, 2 vs. 3–5) and diameter of the largest tumor (< 2 cm vs. ≥ 2 cm), we randomly assigned patients (1:1) to receive daily irradiation (Arm 1), or irradiation at two- to three-day intervals (Arm 2). Both arms are performed with total dose of 27-30 Gy in 3 fractions. The primary endpoint is an intracranial local control rate, defined as intracranial local control at initially treated sites. We use a randomized phase II screening design with a two-sided α of 0∙20. The phase II trial is positive with p < 0.20. All analyses are intention to treat. This study is registered with the UMIN-clinical trials registry, number UMIN000048728. Discussion This study will provide an assessment of the impact of SRT interval on local control, survival, and toxicity for patients with 1–5 BM. The trial is ongoing and is recruiting now. Trial registration UMIN000048728. Date of registration: August 23, 2022. https://center6.umin.ac.jp/cgi-bin/ctr/ctr_view_reg.cgi?recptno=R000055515.

show abstract

“…The jaws open up and close down from/to a minimal value of 1 cm at the beginning and end of the treatment, with the fixed nominal jaw width in between to reduce longitudinal dose penumbra. [19][20][21][22][23][24][25] Several additional delivery features are available on the Radixact delivery system. 26 While the jaw settings and gantry periods remain the same, the nominal dose rate of Radixact has increased from 850 to 1000 cGy/min.…”

Section: New Delivery and Imaging Modalities (With Hardware Enhanceme...mentioning

confidence: 99%

AAPM Task Group Report 306: Quality control and assurance for tomotherapy: An update to Task Group Report 148

et al. 2023

View full text Add to dashboard Cite

Since the publication of AAPM Task Group (TG) 148 on quality assurance (QA) for helical tomotherapy, there have been many new developments on the tomotherapy platform involving treatment delivery, on-board imaging options, motion management, and treatment planning systems (TPSs). In response to a need for guidance on quality control (QC) and QA for these technologies, the AAPM Therapy Physics Committee commissioned TG 306 to review these changes and make recommendations related to these technology updates. The specific objectives of this TG were (1) to update, as needed, recommendations on tolerance limits, frequencies and QC/QA testing methodology in TG 148, (2) address the commissioning and necessary QA checks,as a supplement to Medical Physics Practice Guidelines (MPPG) with respect to tomotherapy TPS and (3) to provide risk-based recommendations on the new technology

show abstract

Efficacy of stereotactic radiotherapy for brain metastases using dynamic jaws technology in the helical tomotherapy system

Cited by 6 publications

References 15 publications

Specific Approaches to Planning of Patients With Primary and Secondary Brain Tumors Using the Tomotherapy Planning System

Specific Approaches to Planning of Patients With Primary and Secondary Brain Tumors Using the Tomotherapy Planning System

Daily irradiation versus irradiation at two- to three-day intervals in stereotactic radiotherapy for patients with 1-5 brain metastases: study protocol for a multicenter open-label randomized phase II trial

AAPM Task Group Report 306: Quality control and assurance for tomotherapy: An update to Task Group Report 148

Contact Info

Product

Resources

About